Shots:

• The open-label- HYPHOP study involves assessing Keveyis vs PBO in patients with PPP- following 9wks. controlled study. The results are published in the journal- Muscle & Nerve
• The results from post hoc analyses of the HYPHOP study confirmed that the therapy is safe and effective for chronic use- efficacy was maintained @61wks.- reduction in attacks rates in patients receiving Keveyis continuously than among those switching from PBO to Keveyis after 9wks.
• Additionally- AEs analyses indicate no new safety signals in the 52wks. of the study compared to the first 9 wks. while results reinforce the utility of Keveyis as an effective option to treat PPP

  Ref: Globe Newswire | Image: Businesswire